摘要
目的评价131I在老年甲状腺功能亢进(简称甲亢)性心脏病治疗中的临床价值。方法 95例老年甲亢性心脏病患者行131I口服治疗并于131I治疗前、治疗后3、6个月及1年复查甲状腺功能。在治疗前及治疗后1年分别行门控心血池显像,以评价治疗效果。结果甲亢治愈率97.89%,阵发性房颤治愈率为100.00%,持续性房颤治愈率为84.00%。治疗前游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)水平分别与治疗后3、6、12个月比较,差异均有统计学意义(P<0.05)。治疗前左室收缩及舒张功能参数与治疗1年后比较,差异有统计学意义(P<0.05),左心室收缩及舒张功能明显改善。结论老年甲亢性心脏病患者选择放射性131I治疗,是改善甲亢性心脏病的关键,能够有效控制FT3、FT4、TSH水平,改善老年甲亢性心脏病患者的心功能。
Objective To evaluate the clinical value of ^131I in the treatment of senile hyperthyroid heart disease. Methods 95 cases of elderly hyperthyroid heart disease were orally treated by ^131I. The thyroid function was detected before lali therapy and in 3 months,6 months and 1 year after treatment. The gated blood pool imaging was performed before treatment and in 1 year after treatment for evaluating the therapeutic effect. Results The cure rate was 97.89 % for hyperthyroidism, 100.00% for paroxysmal atrial fibrillation and 84.00% for persistent atrial fibrillation. FT3, FT4 and TSH levels had statistical difference between before treatment and in 3,6,12 months after treatment （P〈0.05）. The left ventricular systolic and diastolic function parameters had statistical differences between before treatment and in 1 year after treatment （P〈0. 05）. The left ventricular systolic and diastolic function was improved significantly. Conclusion Selecting radioactive ^131I for treating elderly hyperthyroid heart disease is the key to improve hyperthyroid heart disease,can effectively control the FT3,FT4 and TSH levels and improve the heart function.
出处
《重庆医学》
CAS
CSCD
北大核心
2013年第25期2959-2960,2963,共3页
Chongqing medicine
